Overview

This trial is active, not recruiting.

Conditions myasthenia gravis, thymoma
Sponsor Charite University, Berlin, Germany
Start date August 2007
End date December 2016
Trial size 80 participants
Trial identifier NCT01102192, Thymus in myasthenia gravis

Summary

Although the association between thymic hyperplasia / thymoma and autoimmune myasthenia gravis has been known for some time, the question of causality remains uncertain. Recent research findings indicate, however, that especially in myasthenia patients with thymomas a non-physiological export of naive CD4 + T-cells can take place by the tumour and this could possibly play an important role in the pathogenesis of myasthenia gravis. The investigators want to analyse the functionality and specificity of t-cells generated in thymomas as well as the effect of thymectomy on the immune system.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Arm
Myasthenia gravis with thymoma
Myasthenia gravis without thymoma
Thymoma without Myasthenia gravis
cardiac, or thyroid surgery

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with compelling indications for thymectomy due to thymoma (with or without myasthenia gravis), Or - Patients with elective indication for thymectomy due to thymoma without myasthenia gravis - Patients with indication for a heart or thyroid surgery, in which for op-technical reasons, a (partial) resection of the thymus is performed. - Signed informed consent form - Age > 17 Years Exclusion Criteria: - Other immunological diseases such as rheumatoid arthritis, multiple sclerosis

Additional Information

Principal investigator Andreas Meisel, MD
Description On one hand we want to perform a detailed analysis of the T-cells generated in thymomas in terms of their functional capacity and their specificity. We will analyse blood and thymoma tissue of patients with myasthenia gravis with thymona, patients with myasthenia gravis without thymona, and patients with thymona without myasthenia gravis. Hypothesis: The T-cells which are generated in the thymoma in thymoma-associated myasthenia gravis can be differentiated from T-cells which are generated in normal thymoma tissue with regard to functionality and T-cell receptor specificity. This non-physiological T-cell maturation might be the cause for the formation of auto-antibodies. On the other hand we want to examine the effects of thymectomy on the immune system in the context of myasthenia gravis. We will analyse blood and thymoma tissue of patients with myasthenia gravis with thymona, patients with myasthenia gravis without thymona, patients with thymona without myasthenia gravis and patients with cardiac, or thyroid surgery. Hypothesis: 1. Thymectomy in patients with myasthenia gravis leads to a reduced number of auto-reactive, e.g. Acetylcholine receptor (ACh-R)-specific T cells. In contrast, T-cells with other specifities, for example against CMV or tetanus, are not affected. 2. The non-physiological export of thymocytes from thymomas leads to a significant shift in leukocyte populations in peripheral blood.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Charite University, Berlin, Germany.